Visterra is a clinical-stage biopharmaceutical company focused on applying its novel Hierotope platform to identify unique disease targets and to design and engineer innovative antibody-based therapies that are intended to be effective as a single-dose administration. It also provides a structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry.